NCT02123706: A Phase IIa, Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-ischemic Etiology |
|
|
| Recruiting | 2a | 20 | US | Human Allogeneic Mesenchymal Stem Cells, Mesenchymal Stem Cells, Marrow Stromal Cells, Placebo, Lactated Ringer's Solution | Stemedica Cell Technologies, Inc., CardioCell, LLC; A Stemedica Company | Non-ischemic Heart Failure | 06/16 | 06/16 | | |
NCT04956809: Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure |
|
|
| Completed | 2 | 3 | US | Dapagliflozin 10Mg Tab, Placebo | University of Pennsylvania, Amgen | HFrEF | 06/23 | 06/23 | | |
| Enrolling by invitation | N/A | 40 | US | | University of Pennsylvania, Amgen | Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure | 06/25 | 08/25 | | |
